Suraksha Diagnostic: Press Release in respect of Unaudited(Standalone & Consolidated) Financial Results for the quarter ended…
Suraksha Diagnostic (SURAKSHA) filed a disclosure titled "Press Release in respect of Unaudited(Standalone & Consolidated) Financial Results for the quarter ended 30th September 2026". The company is valued at about ₹1,790 crore.
What happened
Suraksha Diagnostic (SURAKSHA) filed a disclosure with the exchanges on 10 November 2026 at 05:16 PM titled "Press Release in respect of Unaudited(Standalone & Consolidated) Financial Results for the quarter ended 30th September 2026".
Company snapshot
Suraksha Diagnostic is a small-cap company, with a market value of about ₹1,790 crore.
The stock last traded at ₹343.7, against a 52-week range of ₹224.1–₹360 (4.5% below the high).
Before this filing the shares had moved +11.1% over the month and +37.7% over three months. Average daily turnover over the last 20 sessions was about ₹1.17 crore.
Promoters held 49.10% at the end of Q1 FY27; 0.10% of promoter shares were pledged. Foreign institutions owned 13.47% and domestic institutions 23.23%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 73 | 9.4 | 1.8 |
| Q2 FY26 | 79 | 9 | 1.73 |
| Q3 FY26 | 76 | 8.1 | 1.56 |
| Q4 FY26 | 81 | 6.3 | 1.21 |
| Q1 FY27 | 88 | 13 | 2.5 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Market-wide, 11,356 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 10 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.